Fig. 2From: A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case reportImmunohistochemical (IHC) analysis showed PD-L1 was expressed in 20–30% of lung tumor cells of this patient (a, b) as compared with the positive control (c). The antibody of PD-L1 (VentanaSP263) was purchased from Roche, San Francisco, CA, USA)Back to article page